Incyte Corporation (INCY)
NASDAQ: INCY
· Real-Time Price · USD
60.77
1.79 (3.03%)
At close: May 12, 2025, 3:59 PM
59.09
-2.76%
After-hours: May 12, 2025, 06:52 PM EDT
Incyte Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I C L U S I G Revenue | 114.32M | 105.84M | 4.67M | 105M | 89.95M | 79.94M | 66.9M | 29.6M | 49M | 28.3M | 3.7M |
| I C L U S I G Revenue Growth | +8.01% | +2167.31% | -95.55% | +16.73% | +12.53% | +19.49% | +126.01% | -39.59% | +73.14% | +664.86% | n/a |
| J A K A F I Revenue | 3.21B | 2.74B | 337.99M | 2.22B | 1.91B | 1.58B | 1.1B | 852.8M | n/a | n/a | n/a |
| J A K A F I Revenue Growth | +17.15% | +710.91% | -84.75% | +15.95% | +20.82% | +43.79% | +28.99% | n/a | n/a | n/a | n/a |
| M I N J U V I Revenue | 119.24M | 19.65M | 68.53M | 205M | 77.5M | 180M | n/a | n/a | n/a | n/a | n/a |
| M I N J U V I Revenue Growth | +506.68% | -71.32% | -66.57% | +164.52% | -56.94% | n/a | n/a | n/a | n/a | n/a | n/a |
| Milestone And Contract Revenue Revenue | 43M | 165M | 95M | 110.92M | 80.42M | 40.09M | n/a | n/a | n/a | n/a | n/a |
| Milestone And Contract Revenue Revenue Growth | -73.94% | +73.68% | -14.35% | +37.92% | +100.63% | n/a | n/a | n/a | n/a | n/a | n/a |
| Olumiant Royalty Revenue | 135.57M | 134.55M | 220.88M | 25.88M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Olumiant Royalty Revenue Growth | +0.76% | -39.08% | +753.33% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| OPZELURA Revenue | 508.29M | 128.74M | 4.91M | 4.14M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| OPZELURA Revenue Growth | +294.84% | +2521.89% | +18.48% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PEMAZYRE Royalty Revenues Revenue | 83.92M | 84.65M | 109.39M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PEMAZYRE Royalty Revenues Revenue Growth | -0.86% | -22.62% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Tabrecta Royalty Revenues Revenue | 22.75M | 15.41M | 10.39M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Tabrecta Royalty Revenues Revenue Growth | +47.60% | +48.34% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| ZYNYZ Revenue | 3.19M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| ZYNYZ Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 325.69M | 326.8M | 309.2M | 289.63M | 300.3M | 293.9M | 267.89M | 283.9M | 315.61M | 272.82M | 266.5M | 253.28M | 209.58M | 226.2M | 190.7M | 168.9M | 153.79M | 166.99M | 120.8M | 118M | 111.15M | 136.18M | 102.61M | 105.94M | 123.98M | 108.36M | 96.52M | 108.03M | 121.5M | 97.83M | 91.27M | 90.07M | 87.23M | 96.08M | 75.78M | 66.79M | 64.6M | 52.47M | 47.6M | 51.68M | 44.87M |
| Selling, General, and Administrative Revenue Growth | -0.34% | +5.69% | +6.76% | -3.55% | +2.18% | +9.71% | -5.64% | -10.05% | +15.68% | +2.37% | +5.22% | +20.85% | -7.35% | +18.62% | +12.91% | +9.82% | -7.90% | +38.24% | +2.37% | +6.16% | -18.38% | +32.72% | -3.15% | -14.55% | +14.42% | +12.26% | -10.65% | -11.09% | +24.19% | +7.19% | +1.33% | +3.25% | -9.21% | +26.80% | +13.45% | +3.40% | +23.12% | +10.23% | -7.89% | +15.17% | n/a |
| Research and Development Revenue | 437.28M | 466.03M | 573.17M | 1.14B | 429.26M | 444.49M | 375.71M | 400.75M | 406.64M | 501.36M | 384.01M | 347.2M | 353.37M | 472.83M | 334.94M | 343.51M | 306.9M | 405.94M | 438.11M | 286.6M | 1.09B | 312.87M | 281.34M | 289.36M | 270.55M | 304.24M | 292.53M | 298.09M | 303.1M | 446.94M | 269.61M | 201.84M | 407.97M | 161.59M | 143.18M | 120.27M | 156.82M | 116.63M | 132.07M | 112.44M | 118.36M |
| Research and Development Revenue Growth | -6.17% | -18.69% | -49.65% | +165.20% | -3.43% | +18.31% | -6.25% | -1.45% | -18.89% | +30.56% | +10.60% | -1.75% | -25.26% | +41.17% | -2.49% | +11.93% | -24.40% | -7.34% | +52.86% | -73.59% | +246.88% | +11.21% | -2.77% | +6.96% | -11.07% | +4.00% | -1.87% | -1.65% | -32.18% | +65.77% | +33.58% | -50.53% | +152.48% | +12.85% | +19.05% | -23.31% | +34.46% | -11.69% | +17.46% | -5.00% | n/a |